Top news of the week: 10.01.2023.
Money troubles and M&A: What’s on biotech insiders’ minds ahead of a not-so-celebratory JPM week
Nearly 70% of biotech insiders say financing — such as raising venture capital or launching an IPO — will be a challenge in 2023.
FutureCast: Noubar Afeyan in conversation with Aviv Regev
Join us as Noubar Afeyan, Founder and CEO of Flagship Pioneering sits down with Aviv Regev, Head, Executive Vice President, Genentech Research and Early Development, to talk about the ...
FDA approves Alzheimer’s drug shown to moderately slow cognitive decline in early stages of the disease
Eisai's newly approved Alzheimer's drug, Leqembi, has limitations but is groundbreaking in a field that hasn’t seen real medical progress in decades.
FDA Grants Priority Review to Genentech’s Bispecific Antibody Glofitamab for People With Relapsed or Refractory Large B-Cell Lymphoma
Discover the latest news about our company, our products, our policies, and our people.
Biotech Startup Acelyrin Buys Drugmaker ValenzaBio in Stock Deal
Acelyrin, backed with more than $550 million in venture capital, adds to drug pipeline with acquisition.
Nucleate announces Eli Lilly and Company as a new Platinum Sponsor of the 2023 Activator program
BOSTON (PRWEB) January 05, 2023 -- Nonprofit organization dedicated to empowering future biotech leaders, announced that Eli Lilly and Company (NYSE: LLY) will be a Platinum Sponsor of the ...
Ensoma buys a startup to advance ‘in vivo’ cell therapy work
The Takeda-backed biotech revealed it’s raised $85 million in new funding alongside announcing the acquisition of gene editing startup Twelve Bio.
Belharra debuts with $130M in funding, Genentech partnership
The Versant-backed company emerged from stealth with technology it says can help it better identify small molecule drugs for any target on any protein.